Cappariloside A
Cappariloside A is a larvicide that exhibits larvicidal activity against Aedes aegypti larvae and reduces larval glutathione-S-transferase activity. Cappariloside A also possesses antiviral activity, decreases the level of phosphorylated STAT1 in cells, inhibits the replication of influenza viruses H1N1, H3N2, PIV3 and ADV, and downregulates the expression of IL-6, IP-10, MIG, RANTES/CCL-5, IFN-β and IL-29. Cappariloside A suppresses the inflammatory response induced by mouse lung-adapted influenza virus strains. Cappariloside A can be used in studies related to larvicidal applications and influenza virus infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 229483-41-4
- Formule: C16H18N2O6
- Masse moléculaire:334.32
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Cappariloside A (Compound 1) (24-48 h) exhibits larvicidal activity against 3rd-instar *Aedes aegypti* larvae, with an LC50 value of 71.14 ppm[1].
Cappariloside A (71.14 ppm; 24 h) reduces the activity of glutathione-S-transferase in surviving 3rd-instar *Aedes aegypti* larvae[1].
Cappariloside A (0-400 μg/mL; 72 h) inhibits the replication of influenza A virus strain A/PR/8/34 (H1N1) in MDCK cells, with an IC50 value of 115.25 μg/mL[2].
Cappariloside A (48 h) exhibits potent antiviral activity against human influenza virus subtypes A/PR/8/34 (H1N1), A/GZ/GIRD07/09 (H1N1 pdm2009) and A/HK/8/68 (H3N2) in MDCK cells, with IC50 values of 288.03, 362.18 and 375.73 μg/mL, and SI values of 4.36, 3.37 and 3.34, respectively[2].
Cappariloside A exhibits antiviral activity against PIV3 in LLC-MK2 cells (IC50 = 757.86 μg/mL, SI = 1.32), and against ADV3 in A549 cells (IC50 = 382.23 μg/mL, SI = 3.32)[2].
Cappariloside A (0-4 mg/mL; 6-72 h) inhibits the progeny replication of influenza A virus strain A/PR/8/34 (H1N1) in 16HBE cells, and suppresses virus-induced expression of IL-6, IP-10, MCP-1 and RANTES/CCL-5 at doses as low as 0.25 mg/mL[2].
Cappariloside A (0.25-2 mg/mL; 24, 48 h) inhibits the progeny replication of influenza A virus A/PR/8/34 (H1N1) in RAW264.7 cells, and suppresses the virus-induced expression of IP-10 and RANTES/CCL-5 at concentrations of 1 mg/mL and 0.5 mg/mL[2].
Cappariloside A (0-1 mg/mL; 24 h) inhibits the expression of IP-10 and RANTES/CCL-5 in 16HBE cells induced by avian influenza virus H9N2, but does not suppress viral replication[2].
Cappariloside A (0-2 mg/mL; 24 h) inhibits LPS (HY-D1056)-induced expression of IP-10, IL-6 and RANTES/CCL-5 in RAW264.7 cells without affecting TNF-α levels[2].
Cappariloside A (0-2 mg/mL; 6, 24, 48, 72 h) regulates the host IFN signaling pathway in 16HBE cells by inhibiting virus-induced STAT1 phosphorylation, reducing the expression of IFN-β and IL-29, and suppressing IFN-β-induced expression of IP-10 and RANTES/CCL-5[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human bronchial epithelial (16HBE) cells infected with avian influenza virus A/Chicken/Guangdong/1996 (H9N2)
-
Concentration:1, 0.5, 0.25 mg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced H9N2-induced protein levels of IP-10 and RANTES/CCL-5 in a dose-dependent manner, despite no inhibition of H9N2 replication.
-
Cell Line:Murine macrophage (RAW264.7) cells stimulated with lipopolysaccharide (LPS)
-
Concentration:2, 1 mg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced LPS-induced protein levels of IP-10, IL-6, and RANTES/CCL-5 in a dose-dependent manner, with no effect on TNF-α levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-8 weeks old)[2]
-
Dosage:75-300 mg/kg/day
-
Administration:p.o.; twice daily; 5 days
-
Result:Inhibited influenza-induced weight loss at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited influenza-induced weight loss at day 3 post-infection at 150 and 75 mg/kg·day.
Reduced pulmonary index by 50% at day 5 post-infection at 300 mg/kg·day; reduced pulmonary index by 30% at day 5 post-infection at 150 mg/kg·day; reduced pulmonary index by 20% at day 5 post-infection at 75 mg/kg·day.
Inhibited total protein concentration increase in bronchoalveolar lavage fluid (BALF) at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited total protein concentration increase in BALF at day 3, 5, and 7 post-infection at 150 mg/kg·day; inhibited total protein concentration increase in BALF at day 3 and 5 post-infection at 75 mg/kg·day.
Reduced inflammatory cell infiltration, inflammatory area, and pathology score in lung tissue at 300 mg/kg·day.
Decreased total white cell counts in BALF at day 5 post-infection at 300, 150, and 75 mg/kg·day.
Inhibited influenza-induced IL-6 and IP-10 levels in BALF at day 3, 5, and 7 post-infection at 300 mg/kg·day; inhibited influenza-induced IL-6 and IP-10 levels in BALF at day 3 and 5 post-infection at 150 and 75 mg/kg·day.
Chemical Information
-
CAS No. 229483-41-4
-
Masse moléculaire 334.32
-
Formule C16H18N2O6
-
SMILES
N#CCC1=CNC2=CC=CC(O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)=C21
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cappariloside A Related Classifications
HY-N17963 Related Classifications
Powered by Bioz